Summary of "These Molecules Reversed Aging by... YEARS! [TRIIM Study Explained - Study 216]"

Scientific Concepts, Discoveries, and Phenomena Presented

TRIIM Study Overview

Conducted at Stanford Medical School and published in 2019.
Involved 10 healthy men aged 50-65.
Investigated whether a cocktail of molecules could improve health markers, focusing on immune health and epigenetic aging.
The study lasted roughly 18 months, with some measurements taken up to 12 months.

Key Biological Measures and Findings

C-Reactive Protein (CRP): A liver-secreted inflammatory marker that dropped by 30-40% at 9 and 12 months, indicating reduced inflammation.
Kidney Function: Measured by glomerular filtration rate (GFR), which showed improvement starting at 9 months.
Blood Insulin and Glucose: No significant changes were observed.
Thymic Involution and Regeneration:
- The thymus is crucial for maturing T cells (adaptive immune system).
- It naturally shrinks and fills with fat by age 60-65 (a process called thymic involution).
- The molecular cocktail appeared to reverse this fat infiltration in about 80% of participants, increasing the fat-free thymic tissue fraction (TFFF), especially noticeable between 5 to 9 months.
Immune Cell Profile:
- Focused on monocytes (innate immune system cells) expressing CD38, a marker of pro-inflammatory state.
- There was a significant reduction in CD38+ monocytes over the 12-month period, suggesting lowered systemic inflammation.
- Data on T cells was less convincing and considered overinterpreted by the presenter.

Epigenetic Aging and Clocks

Epigenetic clocks track DNA methylation patterns that correlate strongly with biological age.
The study showed significant reversal in epigenetic age, especially from months 9 to 12.
Participants experienced an average reversal of biological age by about 6.5 years according to epigenetic markers.
This epigenetic age reversal coincided with improvements in CRP and kidney function, suggesting a meaningful biological effect.

Molecular Cocktail Administered

Human Growth Hormone (0.015 mg/kg)
DHEA (50 mg)
Metformin (500 mg)
Vitamin D (3000 IU)
Zinc (50 mg)

Concerns about human growth hormone potentially promoting cancer were addressed; prostate cancer markers (PSA) improved, though liver enzyme alkaline phosphatase slightly increased, which remains unexplained.

Future Directions

The study is currently in a phase two clinical trial with more participants.
Outcomes are expected by the end of 2024.
More comprehensive data and replication are needed to confirm findings.

Methodology Outline

Selection of 10 healthy men aged 50-65.
Administration of a molecular cocktail (GH, DHEA, Metformin, Vitamin D, Zinc).
Longitudinal measurements over approximately 18 months, focusing on:
- Inflammatory markers (CRP)
- Kidney function (GFR)
- Immune system metrics (thymic fat-free fraction, CD38+ monocytes, T cells)
- Epigenetic age using multiple epigenetic clocks
Comparison of baseline to multiple time points, especially at 9 and 12 months.

Researchers and Sources Featured

Stanford Medical School researchers conducting the TRIIM study.
The video presenter (unnamed) who analyzed and explained the study data.
A “physionic Insider” who introduced the study to the presenter.

This summary captures the key scientific findings and concepts from the TRIIM study on molecular intervention to reverse aging markers, focusing on immune system rejuvenation and epigenetic age reversal.